Concepts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluoroalkane β-agonists

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 6, 1999, Pages

  Parameswaran, Krishnan ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Bioequivalence; Inhaled agonist

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROFLUOROCARBON; FLUORINATED HYDROCARBON; SALBUTAMOL;

ARTICLE; BIOEQUIVALENCE; BRONCHODILATATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG POTENCY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; PRIORITY JOURNAL;

EID: 0033437147     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(99)70039-4     Document Type: Article

References (15)

1. 1. Montreal Protocol on substances that deplete the ozone layer: 1997. Technology and economic assessment panel, volumes I, II. The Netherlands, United Nations Environmental Programme.
2. 2. British Association of Lung Research. Determining equivalence of inhaled medications. Respir Med 1995;89:253-61.
3. 3. Wong BJO, Hargreave FE. Bioequivalence of metered-dose inhaled medications. J Allergy Clin Immunol 1993;92:373-9.
4. 4. Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Pharmacol 1992;34:311-5.
5. 5. Britton J, Hanley SP, Garrett HV, Hadsfield JW, Tattersfield AE. Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma. Thorax 1988;43:300-5.
6. 6. Wong AG, O'Byrne PM, Lindbladh C, Inman MD, Stahl E, Hargreave FE. Dose-response protective effect of salbutamol on methacholine airway responsiveness using pressurized metered dose inhalers and turbuhalers. Can Respir J 1998;5:119-23.
7. 7. Ahrens RC, Harris JB, Milavetz G, Annis L, Ries R. Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. J Allergy Clin Immunol 1987;79:876-82.
8. 8. Finney DJ. Statistical methods in biological assay. 3rd edition. London: Charles Griffin and Co Ltd; 1978.
9. 9. Kleerup EC, Tashkin DP, Cline AC, Ekholm BP. Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Chest 1996;109:702-7.
10. 10. Dockhorn R, Vanden Burgt JA, Ekholm BP, Donnell D, Cullen MT. Clinical equivalence of a novel non-chlorofluorocarbon - containing salbutamol metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma. J Allergy Clin Immunol 1995;96:50-6.
11. 11. Tinkelman DG, Bleecker ER, Ramsdell J, et al. Proventil HFA and Ventolin have similar safety profiles during regular use. Chest 1998;113:290-6.
12. 12. Foster RW, Atanga GK, Carpenter JR, Evans DE, Rakshi K, Small RC. A method for bioassay of potency and effectiveness of inhaled bronchodilators in normal subjects. Br J Clin Pharmacol 1991;31:445-55.
13. 13. Jenkins M. Clinical evaluation of CFC-free metered dose inhalers. J Aerosol Med 1995;8(suppl):S41-7.
14. 14. Ahrens R, Stewart B, Frosolono M, et al. Evaluation of bioequivalence of a generic albuterol metered-dose inhaler and Ventolin MDI using histamine challenge [abstract]. Am J Respir Crit Care Med 1997;155:A667.
15. 15. Parameswaran K, Inman MD, Ekholm BP, et al. Protection against methacholine bronchoprotection to assess relative potency of inhaled beta-2 agonist. Am J Respir Crit Care Med 1999;160:354-7.